Effect of difinitive chemoradiation with cisplatin-irrinotecan or carboplatin-paclitaxol in esophageal cancer

Phase 3

Recruiting

• Conditions: Chemoradiation Protocols.; ??? ???????_??? ????_??????; C15.1-C15.

• Registration Number: IRCT2014110219783N1
• Lead Sponsor: Vice chancellor for research, Mashhad University of Medical Sciencesice

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Iinclusion criteria:Primery Esophageal or Cardioesoohageal ?Cancer(Adenocarcinoma or Scc);Without eny distant metastas;Maximum age 75 years ;Performance Status>70% ;Hemotologically Stable; Normal liver and kidney function; Patient Satisfaction; Unfit patient for surgery.
Exclusion Criteria;Metastatic disease; Cervical Esophageal Cancer; Thracheoesophageal fistula; Another previous or current malignant disease ; Any surgery performed within the past 4 weeks; According to the judgment of physition.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival Rate. Timepoint: 1-Every 3 monthes after start of intervention2-Following every cycle of chemothrapy. Method of measurement: 1-Monthes that patients survive after intervention2-Questionnaire.

Secondary Outcome Measures

Name	Time	Method
1-Disease Free Survival 2-toxcicity. Timepoint: 1-Every 3 months after start of intervention 2-Following every cycle of chemothrapy. Method of measurement: Monthes that patients survive after start of intervention-qestionnaire.